Willow Biosciences Reports 2024 Financial Results and Subsidiary Sale

The latest announcement is out from Willow Biosciences Inc ( (TSE:WLLW) ).

Willow Biosciences Inc. reported its financial results for 2024, showing a significant increase in revenue but also a net loss, indicating financial challenges. The company announced the sale of its operating subsidiary, Epimeron, which includes its business operations and intellectual property, to a UK-based entity. This sale will result in Willow no longer meeting the Toronto Stock Exchange’s listing requirements, leading to a review process and potential suspension. The transaction is expected to impact the company’s operations significantly, including the termination of key executives.

More about Willow Biosciences Inc

Willow Biosciences Inc. is a biotechnology company that develops and produces precision fermented ingredients for the health and wellness, food and beverage, and personal care markets. Utilizing its FutureGrown™ and BioOxi™ platforms, Willow focuses on large-scale production with sustainability, offering bio-based manufacturing processes to benefit B2B partners and their customers.

YTD Price Performance: -50.0%

Average Trading Volume: 393,395

Technical Sentiment Signal: Buy

Current Market Cap: C$4.35M

For a thorough assessment of WLLW stock, go to TipRanks’ Stock Analysis page.